7 December 2015
Institute of Fundamental Medicine and Biology (IFMB),
Kazan (Volga-region) Federal University
74 Karl Marx Street, Kazan
8.00 – 8.55 Registration
9.00 – 11.00 Morning Plenary I
Evidence-based medicine, Cochrane and society:
international experience and moving forward
9.00 9.15 | Opening and Welcome |
9.15 9.55 | Trusted evidence. Informed decisions. Better health: Where does Cochrane go from here? M. Wilson (London, UK) |
9.55 10.15 | Evidence-based medicine in Russia MoH representatives (Moscow, Russia) |
10.15 10.25 | Cochrane Russia – objectives and perspectives for development L.E. Ziganshina (Kazan, Russia) |
10.25 10.45 | Cochrane evidence for public health interventions E. Von Elm (Lausanne, Switzerland.) |
10.45 11.00 | Discussion, questions |
11.00 – 11.30 Morning break
11.30 – 13.00 Morning Plenary II
Evidence-based medicine, Cochrane and society:
international experience and moving forward
11.30 11.45 | The importance of evidence and the legacy of Archie Cochrane E.J. Burger (Washington, USA) |
11.45 12.15 | Cochrane evidence for health: European perspective Guillaume Dedet, WHO EURO (Copenhagen, Denmark) |
12.15 12.35 | EBM principles in prevention of non-communicable diseases O. S. Medvedev (Moscow, Russia) |
12.35 13.00 | Cochrane Library: An inroduction Branka Mrljes (Oxford, UK) Discussion, questions |
\r
13.00 – 14.00 Lunch break. Poster session.
14.00 – 15.30 Parallel oral sessions «Producing and using evidence»
Lecture room 1 14.00 – 15.30
Achievements, problems and perspective of Russian speaking countries
14.00 14.10 | Paradoxes of evidence in Russian addiction medicine V.D. Mendelevich (Kazan, Russia) |
14.10 14.20 | Meta-analysis: problems with Russian publications E.V. Verbitskaya (St.-Petersburg, Russia) |
14.20 14.30 | Evidence-based clinical guidelines in the Kyrgyz Republic A.A. Zurdinova (Bishkek, Kyrgyzstan) |
14.30 14.40 | Personalised medicine in Russia V.G. Kukes, M.V. Zhuravleva (Moscow, Russia) |
14.40 14.50 | Comparative effectiveness – modern request for decision-making based on the principles of evidence-based medicine A. Kolbin (St.-Petersburg, Russia) |
14.50 15.00 | Quality of postgraduate medical education I.G. Nizamov, T.I. Sadykova (Kazan, Russia) |
15.00 15.10 | The role of independent information in development of a national formulary N.A. Cebotarenko (Chisinau, Moldova) |
15.10 15.20 | Improving data retrieval quality: evidence-based medicine perspective V. Dobrynin, J. Balykina, M. Kamalov, A. Kolbin, E. Verbitskaya, M. Kasimova (St.-Petersburg, Russia) |
15.20 15.30 | Discussion, questions |
Lecture room 2 14.00 – 15.30
Clinical aspects and patient safety I
14.00 14.30 | Cochrane evidence and pharmacovigilance A. Herxheimer (London, UK) |
14.30 14.40 | The role of evidence in pharmacovigilance V.K. Lepakhin, A.V. Astakhova (Moscow, Russia) |
14.40 14.50 | Acute kidney injury in neonatal intensive care: medicines involved A.I. Safina, M.A. Daminova (Kazan, Russia) |
14.50 15.00 | Diabetes mellitus: curable or not? EBM perspective S.Yu. Kalinchenko (Moscow, Russia) |
15.00 15.10 | CYP3A4 activity and haloperidol effects in alcohol addicts M.S. Zastrozhin (Moscow, Russia) |
15.10 15.20 | Drugs based on natural minerals: possible risks K.S. Golokhvast, V.V. Chaika, A.A. Sergievich, P.F. Kiku (Vladivostok, Russia) |
15.20 15.30 | Discussion, questions |
\r
Lecture room 3 14.00 – 15.30
Clinical aspects and patient safety II
14.00 14.10 | Diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease Ch. Pavlov (Moscow, Russia) |
14.10 14.20 | Mild anemia as a protective factor against pregnancy loss L.O. Buzyan, G.G. Ketova (Chelyabinsk, Russia) |
14.20 14.30 | Antibiotics for skin and soft tissues infections in type 2 diabetes mellitus O.I. Butranova, T.N. Razdrogina (Volgograd, Russia) |
14.30 14.40 | EBM teaching at the Kazan Medical University G. Khasanova (Kazan, Russia) |
14.40 14.50 | Effects of balance training on post-sprained ankle joint instability I. Faizullin, E. Faizullina (Erlangen, Germany; Kazan, Russia) |
14.50 15.00 | Regional specifics of microbial landscape in outpatients with lower respiratory tract infections V.A. Baturin, E.V. Shchetinin, F.T. Malykhin (Stavropol, Russia) |
15.00 15.10 | Adherence to EBM guidelines in clinical practice R.Kh. Khafizianova, I.M. Burykin (Kazan, Russia) |
15.10 15.20 | Experience of a practicing clinical pharmacologist A.Z. Nigmetzyanova (Kazan, Russia) |
15.20 15.30 | Discussion, questions |
\r
Additional oral reports:
1. Implementation of evidence-based pharmacology in a large multidisciplinary hospital and rational use of medicines
S.V. Evstigneev, A.F. Titarenko, T.R. Abakumova, E.G. Alexandrova, V.N. Khaziakhmetova, L.E Ziganshina (Kazan, Russia)
2. Results of pharmacogenetic testing in the Chelyabinsk region
V.O Barysheva (Chelyabinsk, Russia)
3.The results of implementing the principles of evidence-based medicine into republic hospital practice
A.A. Korableva (Kazan, Russia)
4. Evidence-based medicine in the Master's program of classical university, postgraduate education of physicians and health care.
V.N. Khaziakhmetova (Kazan, Russia)
5. Use of the EBM principles in assessing the quality of medical care for compulsory health insurance
L.A.Doronina, E.V. Demyanova (Kazan, Russia)
\r
Lecture room 4 14.00 – 15.30
Basic science aspects:
Molecular mechanisms contributing to the evidence-base
14.00 14.10 | Pirimidine derivatives as hepatoprotective agents A.B. Vyshtakalyuk, N.G. Nazarov, V.V. Zobov, V. E. Semenov, I.V. Galyametdinova, G.V. Tcherepnev, V.S. Reznic (Kazan, Russia) |
14.10 14.20 | Anti-inflammatory and anti-oxidant properties: is there a link? I.Kh. Valeevaa, A.F. Titarenko, V.N. Khaziakhmetova (Kazan, Russia) |
14.20 14.30 | 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease I.V. Zueva, V.E. Semenov, M.A. Mukhamedyarov, S.V. Lushchekina A.D. Kharlamova, E.O. Petukhov, A.S. Mikhailov, S.N. Podyachev, L.F. Saifina, K.A. Petrov, O.A. Minnekhanova, V.V. Zobov E. E. Nikolsky, P. Masson, V.S. Reznik (Kazan, Russia) |
14.30 14.40 | Macrocyclic derivatives of 6-methyluracil: new ligands of the peripheral anionic site of acetylcholinesterase K. Petrov (Kazan, Russia) |
14.40 14.50 | Molecular modeling of mechanism of action of anti-myasthenia gravis slow-binding inhibitor of acetylcholinesterase S. Lushchekina, E. Kots, A. Kharlamov, K. Petrov, P. Masson (Moscow, Kazan, Russia) |
14.50 15.00 | Rat paw oedema modeling and NSAIDs: timing of effects H.H. Cong*, V.N. Khaziakhmetova, L.E. Zigashina (Kazan, Russia) |
15.00 15.10 | Human butyrylcholinesterase polymorphism: molecular modeling S. Lushchekina, H. Delacour, O. Lockridge, P. Masson (Moscow, Russia; Saint Mandé, France; Omaha, USA; Kazan, Russia) |
15.10 15.20 | ATP-induced changes in rat skeletal muscle contractility A.I. Gabdrakhmanov, A.E. Khayrullin, C.H. Grishin, A.U. Ziganshin (Kazan, Russia) |
15.20 15.30 | Discussion, questions |
\r
15.30 – 16.00 Afternoon break
\r
16.00 – 19.00 Afternoon plenary
Cochrane evidence to inform decision-making: achievements and barriers
16.00 16.35 | Evidence based, national clinical guidelines in Denmark: our framework, experience, and the role of Cochrane Karsten Juhl Jørgensen (Copenhagen, Denmark) |
16.35 16.50 | Evidence based pharmacogenetics: is it possible? D.A. Sychev (Moscow, Russia) |
16.50 17.25 | Evidence-based selection of expensive essential medicines: practical implications of the new additions to the WHO Model List of Essential Medicines H.V. Hogerzeil (Groningen, Netherlands,) |
17.25 17.40 | Russian healthcare: myths and reality G.E. Ulumbekova (Moscow, Russia) |
17.40 17.55 | Drug information centres for improving access to independent medicine information L.G. Makalkina (Astana, Kazakhstan) |
17.55 18.20 | WHO Essential Medicines List: some medicines are better than others Lorenzo Moja, WHO Headquarters (Geneva, Switzerland) |
18.20 18.40 | Discussion, questions |
18.40 19.00 | Closure |
